Dr. Umar ( Umar Diabetes Foundation ) (@dromarwahab) 's Twitter Profile
Dr. Umar ( Umar Diabetes Foundation )

@dromarwahab

Consultant Diabetologist & Obesity MSc (UK) Member UK & American Diabetes Assn. Son of a SC JURIST ⚖️ Umar Diabetes Foundation UDF Philanthropist. PTI, IK ,🇵🇰

ID: 504778384

linkhttp://udf.com.pk calendar_today26-02-2012 17:29:05

11,11K Tweet

2,2K Followers

2,2K Following

BilawalBhuttoZardari (@bbhuttozardari) 's Twitter Profile Photo

نبیوں کے ناموں میں نام محمدﷺ عیاں کر رہا ہے مقام محمدﷺ جہاں سر جھکے وہ مقام خدا ہے جھاں دل جھکے وہ مقام محمدﷺ

نبیوں کے ناموں میں نام محمدﷺ
عیاں کر رہا ہے مقام محمدﷺ

جہاں سر جھکے وہ مقام خدا ہے
جھاں دل جھکے وہ مقام محمدﷺ
Scott Isaacs (@scottisaacsmd) 's Twitter Profile Photo

New JAMA Oncology study shows GLP-1 meds linked to reduced #cancer risk in people with obesity. 25% less endometrial cancer, 47% less ovarian cancer, 31% fewer meningiomas. medcentral.com/endocrinology/…

New <a href="/JAMAOnc/">JAMA Oncology</a> study shows GLP-1 meds linked to reduced #cancer risk in people with obesity.  25% less endometrial cancer, 47% less ovarian cancer, 31% fewer meningiomas. medcentral.com/endocrinology/…
Mir Mohammad Alikhan (@mirmakofficial) 's Twitter Profile Photo

کل کہا تھا کہ شاہد عرب اسرائیل کے خلاف متحد ہو جائیں اور آج ہوگئے۔ x.com/chude__/status…

Cristina Tejera (@cristinatejerap) 's Twitter Profile Photo

Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine nejm.org/doi/full/10.10… #EASD2025

Prof. Wasim Hanif (@docwas) 's Twitter Profile Photo

TIRTLE1 Phase 2 Tirzepatide in T1D 8.8% reduction in Weight 0.5% reduction in Hba1c and 35% reduction in Insulin requirements. No severe Hypo or DKA #EASD2025

TIRTLE1 Phase 2 Tirzepatide in T1D 8.8% reduction in Weight 0.5% reduction in Hba1c and 35% reduction in Insulin requirements. No severe Hypo or DKA #EASD2025
Scott Isaacs (@scottisaacsmd) 's Twitter Profile Photo

Phase 3 trial just published in NEJM for #orforglipron, an oral GLP-1 medication for obesity. At the highest dose, participants saw an average 11.2% weight loss, with 36% losing at least 15% and 18% losing at least 20% of their body weight. Cardiometabolic markers also improved.

Phase 3 trial just published in <a href="/NEJM/">NEJM</a> for #orforglipron, an oral GLP-1 medication for obesity. At the highest dose, participants saw an average 11.2% weight loss, with 36% losing at least 15% and 18% losing at least 20% of their body weight. Cardiometabolic markers also improved.
Dr. Umar ( Umar Diabetes Foundation ) (@dromarwahab) 's Twitter Profile Photo

JazakAllah Khair 🙏 Truly Appreciated, Sir. It is through the encouragement and support of individuals like yourself that I remain deeply committed to serving those who deserve the highest standard of care, yet are often deprived due to poverty and limited access to healthcare

Prof. Wasim Hanif (@docwas) 's Twitter Profile Photo

Once-weekly semaglutide 7·2 mg in adults with obesity and type 2 diabetes (STEP UP T2D): a randomised, controlled, phase 3b trial - thelancet.com/journals/landi…

Partha S Kar 🇮🇳🇬🇧🏏🎥 (@parthaskar) 's Twitter Profile Photo

The commitment some have towards their #Racism and #Islamophobia is quite fascinating. Also- for someone 'Lippy'- quite touchy. Happy Sunday to you too. It was a genuine question though 😏 Taj Ali Mukhtar #SundayFunday

The commitment some have towards their #Racism and #Islamophobia is quite fascinating.

Also- for someone 'Lippy'- quite touchy.
Happy Sunday to you too.

It was a genuine question though 😏

<a href="/Taj_Ali1/">Taj Ali</a> <a href="/I_amMukhtar/">Mukhtar</a> 

#SundayFunday
Dr. Umar ( Umar Diabetes Foundation ) (@dromarwahab) 's Twitter Profile Photo

Shame on them…. selfish and unpatriotic. They play for money, not for the pride of Pakistan 🇵🇰. Mohsin Naqvi is a liability… a black hole draining the system. He must be removed immediately. This is beyond tolerance now.